

## POLYMYXIN F, A NEW PEPTIDE ANTIBIOTIC

Sir:

Polymyxin F is a new antibiotic produced by *Bacillus circulans* ATCC No. 31228. Application of the isolation procedure outlined in Chart 1 to 20 liters of fermentation broth gave 0.45 g of the pure antibiotic hydrochloride.

Polymyxin F hydrochloride is a white powder that melts *in vacuo* at 213~219°C. It is freely soluble in water and methanol but insoluble in acetone, benzene, *etc.* Chromatographic mobilities of polymyxin F in a number of systems are listed in Table 1. The antibiotic is detectable by bioautography against *Escherichia coli* or by reagents that give color reactions with primary amines. The optical rotations,  $[\alpha]^{22}(\lambda)$ , of the hydrochloride in 0.5 M HCl (*c* 0.5) are  $-43^\circ$  (589),  $-47^\circ$  (578),  $-54^\circ$  (546),  $-97^\circ$  (436) and  $-160^\circ$  (365 nm). The infrared spectrum in KBr is shown in Fig. 1. The UV spectrum in water has end absorption but no maximum above 200 nm.

Hydrolysis in 6 N HCl at 110°C for 16 hours and amino acid analysis of the hydrolysate indicate that the antibiotic is comprised of 2,4-diaminobutyric acid (Dab), Thr, Ser, Ile, and Leu in a ratio of 5:1:1:1:2. The hydrolysate also contains three extractable fatty acids with relative abundances of 78:19:3. These were identified as 6-methyloctanoic acid, isooctanoic acid and octanoic acid, respectively, by gas-chromatographic comparison of the methyl esters with those obtained from polymyxin B. These hydrolysis products and their relative abundances indicate that the antibiotic is a polymyxin-type molecule and justify naming it as such, even though it is produced by a strain of *Bacillus*

*circulans* rather than a strain of *Bacillus polymyxa*. To the best of our knowledge, no polymyxin has been previously reported with the particular amino acid composition listed above. The antibiotic is presumed to be a mixture of three components, designated polymyxin F<sub>1</sub>, F<sub>2</sub>, and F<sub>3</sub> corresponding to the three fatty acids in order of decreasing abundance. The elemental composition calculated for polymyxin F<sub>1</sub> hydrochloride on the basis of the observed hydrolysis products is in satisfactory agreement with that found for the antibiotic.

*Anal.* Calcd. for C<sub>54</sub>H<sub>105</sub>N<sub>15</sub>O<sub>13</sub>Cl<sub>4</sub>: C, 49.34; H, 8.05; N, 15.99; Cl, 10.79.

Found: C, 49.68; H, 8.05; N, 16.13; Cl (ionic) 10.96%.

Chart 1. Isolation and purification of polymyxin F

Fermented broth	adjust to pH 2 with HCl and centrifuge.
Supernate	extract antibiotic into butanol at pH 2 and concentrate <i>in vacuo</i> .
Extract concentrate	dilute with methanol and precipitate antibiotic with acetone.
Acetone-insoluble powder	adsorb antibiotic on IRC-50 (Na <sup>+</sup> ) resin at pH 7 and elute it with MeOH-H <sub>2</sub> O, 1:1, at pH 1.5 (HCl).
Eluate	concentrate <i>in vacuo</i> to remove MeOH, adjust to pH 10.5 (NaOH), extract into butanol, wash butanol phase with 1 N HCl and remove butanol <i>in vacuo</i>
Polymyxin F, ca. 50% pure	chromatograph on Whatman CM52 carboxymethyl cellulose, eluting with a NaCl gradient and isolating active material as in the previous step.
Polymyxin F hydrochloride	

Fig. 1. Infrared spectrum of polymyxin F hydrochloride in KBr




Table 1. Chromatography of polymyxin F and polymyxin B

System	Rf × 100	
	Polymyxin B	Polymyxin F
Whatman No. 1 paper; BuOH - pyridine - HOAc - water, 15:10:3:12	30	57
Whatman No. 1 paper; BuOH - HOAc - water, 4:1:5 (upper phase)	45	69
Gelman ITLC, type SAF*; PrOH - conc. NH <sub>4</sub> OH, 7:3	62	69
Gelman ITLC, type SAF; PrOH - pyridine - HOAc - water, 15:10:3:12	85	85
Gelman ITLC, type SAF; BuOH - HOAc - water, 3:1:1	27	56

\* Glass microfiber sheets impregnated with silicic acid.

Table 2. Antimicrobial activity of polymyxin F and polymyxin B

Organism	Minimum inhibitory concentration ( $\mu\text{g}/\text{ml}$ )*	
	Polymyxin F hydrochloride	Polymyxin B sulfate
<i>Staphylococcus aureus</i> FDA209P	50	50
<i>Streptococcus pyogenes</i> C203	6.3	4.7
<i>Escherichia coli</i> ATCC10536	2.4	0.1
<i>Escherichia coli</i> SC8294	2.4	0.2
<i>Pseudomonas aeruginosa</i> SC8329	1.6	0.8
<i>Candida albicans</i> SC5314	>100	75

\* Minimum inhibitory concentrations were determined by two-fold broth dilution assay.

The nature of the antibiotic was further explored by 2,4-dinitrophenylation of the amino groups. Amino acid analysis of the acid hydrolysate of the resulting derivative shows that Dab and  $\gamma$ -dinitrophenyl-Dab are produced in a ratio of 1:4. The presence of Dab in this hydrolysate supports the presence of a cyclic peptide. The presence of four amino groups was confirmed by the method of partial substitution<sup>1)</sup>, using dinitrophenylation and separating the mixture of derivatives by electrophoresis<sup>2)</sup>.

Polymyxin F possesses a pattern of antimicrobial activity that is similar to that of polymyxin B as seen from the data in Table 2. The antibiotic, when administered subcutaneously to mice, has an LD<sub>50</sub> of 50 mg/kg but gives protection with an ED<sub>50</sub> of 4.2 mg/kg against an *Escherichia coli* SC8294 infection. Polymyxin

B has an LD<sub>50</sub> of 50 mg/kg and an ED<sub>50</sub> of 1.4 mg/kg in control experiments.

The chemical, physical and biological data that have been obtained for the antibiotic produced by *Bacillus circulans* ATCC 31228 indicate that it is a new member of the polymyxin group<sup>3)</sup>. The most closely related polymyxins are polymyxin D<sup>4)</sup> and polymyxin S<sub>1</sub><sup>5)</sup>, the only other antibiotics of this group that contain serine and that have five instead of six Dab residues.

#### Acknowledgments

We are grateful to Ms. K. RENZ for determination of antimicrobial activity, to Mr. P. A. PRINCIPE for the fermentation, to Mr. F. RUSSO-ALESI for amino-acid analysis, to Ms. M. B. YOUNG for elemental analysis, and to Mr. W. H. TREJO for taxonomy of the producing organism.

WILLIAM L. PARKER  
MARLENE L. RATHNUM  
LORETTA D. DEAN  
MAXWELL W. NIMECK  
WILLIAM E. BROWN  
EDWARD MEYERS

Squibb Institute for  
Medical Research  
P.O. Box 4000  
Princeton, New Jersey 08540  
U.S.A.

(Received June 13, 1977)

#### References

- 1) BATTERSBY, A. R. & L. C. CRAIG: The chemistry of tyrocidine. II. Molecular weight studies. *J. Amer. Chem. Soc.* 74: 4023~4027, 1952
- 2) SILAEV, A. B.; G. S. KATRUKHA & V. M. STEPANOV: Determination of the amino group content of canamycin, mycerin and colimycin.

- Biochem. (USSR) 26: 7~9, 1961
- 3) WILKINSON, S.: *In* the "Kirk-Othmer Encyclopedia of Chemical Technology," 2nd ed, Vol. 16, pp. 306~345, John Wiley & Sons, Inc., New York, N.Y., 1968
  - 4) HAYASHI, K.; Y. SUKETA, K. TSUKAMOTO & T. SUZUKI: Chemical structure of polymyxin D<sub>1</sub>. *Experientia* 22: 354~355, 1966
  - 5) SHOJI, J.; T. KATO & H. HINOO: The structures of two new polymyxin group antibiotics. *J. Antibiotics* 30: 427~429, 1977